Cytori Therapeutics Inc Stock Deutsche Boerse AG
Stocks
US23283K1051
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Market Cap | 29.94M 26.21M 24.19M 22.57M 42.52M 2.83B 43.28M 290M 113M 1.4B 112M 110M 4.87B | P/E 2026 * |
-1.11x | P/E 2027 * | -1.82x |
|---|---|---|---|---|---|
| Enterprise Value | 29.94M 26.21M 24.19M 22.57M 42.52M 2.83B 43.28M 290M 113M 1.4B 112M 110M 4.87B | EV / Sales 2026 * |
4.76x | EV / Sales 2027 * | 1.56x |
| Free-Float |
98.37% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.15% | +5.94% | -3.40% | +2.32% | 46.62B | |
| -2.77% | +10.48% | +409.05% | +600.11% | 40.95B | |
| -0.03% | +12.81% | +22.61% | -14.04% | 32.26B | |
| -1.73% | +3.20% | +17.72% | +59.83% | 32.24B | |
| -3.29% | +2.85% | +13.80% | +30.30% | 25.53B | |
| +1.15% | +11.79% | - | - | 16.38B | |
| -0.96% | +11.85% | +68.73% | +120.51% | 15.27B | |
| +0.56% | +5.09% | +13.43% | +17.88% | 13.61B | |
| -1.74% | +4.34% | +100.68% | +93.25% | 13.34B | |
| Average | -0.85% | +7.53% | +80.33% | +113.77% | 26.24B | |
| Weighted average by Cap. | -0.90% | +7.71% | +94.72% | +137.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.3M 5.51M 5.09M 4.74M 8.94M 595M 9.1M 61.01M 23.69M 294M 23.65M 23.12M 1.02B | 19.14M 16.75M 15.47M 14.43M 27.18M 1.81B 27.67M 186M 72.02M 893M 71.91M 70.31M 3.11B |
| Net income | -26.8M -23.46M -21.65M -20.2M -38.06M -2.53B -38.74M -260M -101M -1.25B -101M -98.44M -4.36B | -18.45M -16.15M -14.91M -13.91M -26.21M -1.74B -26.68M -179M -69.44M -861M -69.33M -67.79M -3B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
